James Love's blog

Videos from TACD's June 25, 2014 side event on intellectual property in the US, EU trade agreement (TTIP)

The following are videos from TACD's June 25, 2014 side event on intellectual property and the proposed Transatlantic Trade and Investment Partnership (TTIP) agreement.

World Health Assembly (WHA 67) agrees to create pooled R&D fund, endorses delinkage of R&D costs from product prices

Today the World Health Assembly (WHA) reached consensus on a "decision", WHA67(15), regarding the Consultative Expert Working Group (CEWG) on Research and Development.

KEI intervention on Library Access to Orphan works, at SCCR 27

KEI and other NGOs attending SCCR 27 have been able to make interventions on various articles in the proposed library treaty. On the issue of library access to orphaned works, KEI's intervention covered the following points, and made a proposal for text.

1. There is ample evidence that national approaches to providing access to orphan works is quite diverse.
2. The diversity of approaches have been used by some to express pessimism that this issue can be addressed in a treaty.

The six countries listed in the Special 301 list, every year, had much higher growth of incomes than USA

According to USTR's 2014 report, six countries have been listed on the Special 301 list "every year since the report's inception." The six countries that have appeared on the Special 301 list every year were Chile, China, India, Indonesia, Thailand and Turkey.

KEI opposes negotiations at WIPO on a broadcasting treaty

KEI comment to SCCR 27 on the proposed Broadcasters Treaty

KEI is a non-profit organization representing consumer and public interests and seeking better outcomes for knowledge governance.

KEI opposes continued discussions in the SCCR on the treaty for broadcasting, for the following reasons.

1. The broadcasting organizations have failed to explain (a) the problem the treaty is supposed to address, (b) how the proposed text is related to the alleged problem.

32 Members of US House of Representatives ask USTR to sanction Canada for not granting patents on drugs

The attached letter, dated April 10, 2014 and signed by a bipartisan group of 32 members of the House of Representatives, asks USTR to elevate Canada to the Special 301 "priority watch list," for "violation of their international obligations" for not granting enough patents on "innovative medicines." According to the members of Congress signing the letter, Canada is in violation of its WTO TRIPS obligations.

KEI comment on ViiV license to Medicines Patent Pool for HIV drug dolutegravir (DTG)

On April 1, 2014, ViiV, a consortium of Pfizer and GSK, and the Medicines Patent Pool (MPP), announced two new licensing agreements that expand generic competition for dolutegravir (DTG), and integrase inhibitor used for the treatment of adult and pediatric HIV infection. (MPP press release here.) Dolutegravir is a new drug, approved for marketing by the US FDA on August 12, 2013.


ZEIT ONLINE has published the EU's July 2, 2013 proposals for TRADE IN SERVICES, INVESTMENT AND E-COMMERCE in the TTIP negotiation. A copy of the proposal is available here. Tags: ISDS, TTIP

Chapter I General provisions
Chapter II Investment
Chapter III Cross border supply of services

Revised agenda for Feb 24 USTR Special 301 hearing

Here is the REVISED agenda for the Special 301 hearing on February 24. Public Citizen has been added to the list of witnesses, and USTR now lists the names of the speakers for the various trade associations. Unlike recent years, the level of participation by major trade organizations is significant.

February 24, 2014 – 10:00 a.m.

Office of the United States Trade Representative
1724 F Street, NW
Washington, D.C. 20508

The Special 301 Hearing is open to the public. Members of the press are welcome to attend.

Alliance for Fair Trade with India (AFTI): Ground zero for trade sanctions against India

The Alliance for Fair Trade with India (AFTI) was created in June 2013, to lobby for "increased action to address the erosion of intellectual property rights ("IPR") in India." According to the group, it is "comprised of organizations representing a range of U.S. industries adversely impacted by India's troubling and frequently discriminatory policies, including manufacturing, agriculture, telecommunications, pharmaceuticals and beyond."

NFTC, a US trade association, asks USTR to sanction China for issuing and enforcing "junk patents" (2014 submission)

A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing "junk patents." The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they

KEI files comments with USTR on 2014 Special 301

Attached in the February 7, 2014, KEI Special 301 Submission.

KEI was a web page with more context on the Special 301 reports, including links to several submissions, and all Special 301 Reports from 1989 to 2013 (all that exist), here: http://keionline.org/ustr/special301

HAI and Medicus Mundi statements at WHO EB on CEWG demonstration projects

Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:

Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination

Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for "western patients who can afford it.”

Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.”

[UPDATE: The latest blog and transcript of Bayer CEO Marijn Dekkers' full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.]

New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms

James K Glassman
James K. Glassman. Merck said Glassman's public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude.
Syndicate content